Nuclear localization of Dpc4 (Madh4, Smad4) in colorectal carcinomas and relation to mismatch repair/transforming growth factor-beta receptor defects.

The tumor-suppressor protein Dpc4 (Smad4, Madh4) regulates gene expression. On binding of an extracellular ligand of the extensive transforming growth factor (TGF) superfamily to its cognate receptor complex, latent cytoplasmic Dpc4 is activated and translocated into the nucleus to function as part of various DNA-binding transcriptional activator complexes. The most relevant ligand/receptor pair to control the tumor suppressive function of Dpc4 remains uncertain, but is usually assumed to be TGF-beta and its heteromeric receptor. We exploited a fortuitous experiment of nature to directly test this hypothesis: the TGF-beta type II receptor gene is inactivated by mutation in nearly all colorectal carcinomas having microsatellite instability, as seen in hereditary nonpolyposis colorectal cancer (HNPCC) and in sporadic medullary colorectal cancers. Using a specific and sensitive immunohistochemical label for Dpc4, we examined nuclear localization of Dpc4 in 13 HNPCC, six medullary, and 41 sporadic nonmedullary colorectal carcinomas. In agreement with published rates, two (5%) of 41 sporadic tumors showed complete loss of Dpc4 protein, indicative of genetic inactivation. All 13 HNPCC and six medullary tumors had intact cytoplasmic and nuclear Dpc4 localization. The TGFBR2 gene was sequenced in three of the cancers from patients with HNPCC, and all of these harbored inactivating mutations. The specificity of the immunohistochemical assay was demonstrated in xenograft tumors of syngeneic cell lines that differed in DPC4 genetic status because of an engineered gene knockout. Thus, nuclear localization of Dpc4 can be maintained in cells with inactivated TGF-beta type II receptors, suggesting the persistence of tumor-suppressive action of an upstream signaling input, most likely a ligand/receptor complex distinct from TGF-beta. Identification of the relevant input would be expected to have implications for the understanding of tumorigenesis and the design of rational biological therapy.

[1]  B. Vogelstein,et al.  The relationship of quantitative nuclear morphology to molecular genetic alterations in the adenoma-carcinoma sequence of the large bowel. , 1992, The American journal of pathology.

[2]  R. Raghow,et al.  Osteogenic protein‐1, a bone morphogenic protein member of the TGF‐β superfamily, shares chemotactic but not fibrogenic properties with TGF‐β , 1994, Journal of cellular physiology.

[3]  L. Aaltonen,et al.  Mutations in the SMAD4/DPC4 gene in juvenile polyposis. , 1998, Science.

[4]  B. Vogelstein,et al.  Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. , 1994, The American journal of pathology.

[5]  S. Kern,et al.  G1 cell cycle arrest and apoptosis induction by nuclear Smad4/Dpc4: phenotypes reversed by a tumorigenic mutation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[6]  K. Kinzler,et al.  Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. , 1995, Science.

[7]  J. Jass,et al.  Pathology of hereditary non-polyposis colorectal cancer. , 1994, Anticancer research.

[8]  P. Howe,et al.  TGF‐β induces fibronectin synthesis through a c‐Jun N‐terminal kinase‐dependent, Smad4‐independent pathway , 1999, The EMBO journal.

[9]  Kathleen R. Cho,et al.  A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. , 1995, Cancer research.

[10]  K. Kinzler,et al.  Targeted deletion of Smad4 shows it is required for transforming growth factor beta and activin signaling in colorectal cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[11]  R. Derynck,et al.  Receptor-associated Mad homologues synergize as effectors of the TGF-β response , 1996, Nature.

[12]  Kohei Miyazono,et al.  TGF-β signalling from cell membrane to nucleus through SMAD proteins , 1997, Nature.

[13]  M. Choti,et al.  Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity. , 2000, The American journal of pathology.

[14]  P. Dijke,et al.  DPC4 (SMAD4) mediates transforming growth factor-β1 (TGF-β1) induced growth inhibition and transcriptional response in breast tumour cells , 1997, Oncogene.

[15]  Scott E. Kern,et al.  DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1 , 1996, Science.

[16]  R. Hruban,et al.  Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. , 1998, Cancer research.

[17]  P. Hoodless,et al.  Targeted Disruption in Murine Cells Reveals Variable Requirement for Smad4 in Transforming Growth Factor β-related Signaling* , 2000, The Journal of Biological Chemistry.

[18]  R. Hruban,et al.  BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. , 2000, The American journal of pathology.

[19]  K. Kinzler,et al.  Analysis of mismatch repair genes in hereditary non–polyposis colorectal cancer patients , 1996, Nature Medicine.

[20]  S. Kern Advances from genetic clues in pancreatic cancer , 1998, Current opinion in oncology.

[21]  A. Sparks,et al.  Immunohistochemical labeling for Dpc4 mirrors genetic status in pancreatic adenocarcinomas: A new marker of DPC4 inactivation , 2000 .

[22]  K. Kinzler,et al.  Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. , 1995, Cancer research.

[23]  Kathleen R. Cho,et al.  DPC4 gene in various tumor types. , 1996, Cancer research.

[24]  Jeffrey L. Wrana,et al.  A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation , 1999, Nature.

[25]  S. Kern,et al.  Transforming growth factor‐β responsiveness in DPC4/SMAD4‐null cancer cells , 1999 .